Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo.
Rozenbaum. René T RT; Su. Linzhu L; Umerska. Anita A; Eveillard. Matthieu M; Håkansson. Joakim J; Mahlapuu. Margit M; Huang. Fan F; Liu. Jianfeng J; Zhang. Zhenkun Z; Shi. Linqi L; van der Mei. Henny C HC; Busscher. Henk J HJ; Sharma. Prashant K PK
Key Findings
- LL‑37 alone had no antibacterial effect against several Staph strains in planktonic (free‑floating) tests.
- In vitro, monolaurin nanocapsules synergized with the peptide DPK‑060 but not with LL‑37.
- Even at the highest peptide loading, the nanocapsule‑LL‑37 combo did not reduce biofilm growth more than each component alone.
- In a mouse wound model, the nanocapsule‑DPK‑060 synergy seen in the lab disappeared, and nanocapsules alone did not speed healing compared to PBS.
Practical Outcomes
- For DIY biohackers, this means that using LL‑37 with monolaurin lipid nanocapsules is unlikely to give any real‑world benefit against Staph biofilms or speed wound healing. In vitro synergy data should be taken with caution, and other antimicrobial strategies should be explored for practical use.
Summary
The research shows that putting the antimicrobial peptide LL‑37 onto monolaurin lipid nanocapsules does not improve fighting Staphylococcus aureus infections in real mice, even though it looked promising in lab dishes. In live animals, the combination didn’t speed wound healing and sometimes performed worse than a simple saline rinse.
Abstract
Bacterial infections are mostly due to bacteria in their biofilm-mode of growth, while penetrability of antimicrobials into infectious biofilms and increasing antibiotic resistance hamper infection treatment. In-vitro, monolaurin lipid nanocapsules (ML-LNCs) carrying adsorbed antimicrobial peptides (AMPs) displayed synergistic efficacy against planktonic Staphylococcus aureus, but it has not been demonstrated, neither in-vitro nor in-vivo, that such ML-LNCs penetrate into infectious S. aureus biofilms and maintain synergy with AMPs. This study investigates the release mechanism of AMPs from ML-LNCs and possible antimicrobial synergy of ML-LNCs with the AMPs DPK-060 and LL-37 against S. aureus biofilms in-vitro and in a therapeutic, murine, infected wound-healing model. Zeta potentials demonstrated that AMP release from ML-LNCs was controlled by the AMP concentration in suspension. Both AMPs demonstrated no antimicrobial efficacy against four staphylococcal strains in a planktonic mode, while a checkerboard assay showed synergistic antimicrobial efficacy when ML-LNCs and DPK-060 were combined, but not for combinations of ML-LNCs and LL-37. Similar effects were seen for growth reduction of staphylococcal biofilms, with antimicrobial synergy persisting only for ML-LNCs at the highest level of DPK-060 or LL-37 adsorption. Healing of wounds infected with bioluminescent S. aureus Xen36, treated with ML-LNCs alone, was faster when treated with PBS, while AMPs alone did not yield faster wound-healing than PBS. Faster, synergistic wound-healing due to ML-LNCs with adsorbed DPK-060, was absent in-vivo. Summarizing, antimicrobial synergy of ML-LNCs with adsorbed antimicrobial peptides as seen in-vitro, is absent in in-vivo healing of infected wounds, likely because host AMPs adapted the synergistic role of the AMPs added. Thus, conclusions regarding synergistic antimicrobial efficacy, should not be drawn from planktonic data, while even in-vitro biofilm data bear little relevance for the in-vivo situation.
Study Information
pubmed
2018
2018-11-19T00:00:00.000Z
10.1016/j.jconrel.2018.11.018
36
52